MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma

NCT07144995 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

1143

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Fruquintinib
Ramucirumab

Interventions

DRUG: Fruquintinib+Paclitaxel
DRUG: Ramucirumab+Paclitaxel

Sponsor

Sun Yat-sen University